Fatemeh Khodadust

Ms. Fatemeh Khodadust

Amsterdam University Medical Centers, Amsterdam, Noord-Holland, The Netherlands

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2020 in Journal of Microbiology, Immunology and Infection
Verified
Journal Article
Open access
AHAhmad Hormati
Ahmad Hormati
ASAlireza Shahhamzeh
Alireza Shahhamzeh
MAMahboubeh Afifian
Mahboubeh Afifian
FKFatemeh Khodadust
Fatemeh Khodadust
SASajjad Ahmadpour
Sajjad Ahmadpour

Verified
Journal Article
Open access
PDF file
FKFatemeh Khodadust
Fatemeh Khodadust
AEAiarpi Ezdoglian
Aiarpi Ezdoglian
MSMaarten Michiel Steinz
Maarten Michiel Steinz
JBJudy van Beijnum
Judy van Beijnum
GZGerben JC Zwezerijnen
Gerben JC Zwezerijnen
CLConny van der Laken
Conny van der Laken
Extensive angiogenesis is a characteristic feature in the synovial tissue of rheumatoid arthritis (RA) from a very early stage of the disease onward and constitutes a crucial event for the development of the proliferative synovium. This process is markedly intensified in patients with prolonged disease duration, high disease activity, disease severity, and significant inflammatory cell infiltration. Angiogenesis is therefore an interesting target for the development of new therapeutic approaches as well as disease monitoring strategies in RA. To this end, nuclear imaging modalities represent valuable non-invasive tools that can selectively target molecular markers of angiogenesis and accurately and quantitatively track molecular changes in multiple joints simultaneously. This systematic review summarizes the imaging markers used for single photon emission computed tomography (SPECT) and/or positron emission tomography (PET) approaches, targeting pathways and mediators involved in synovial neo-angiogenesis in RA.

11 January 2025 in Cells
Verified
Journal Article
Open access
PDF file
FKFatemeh Khodadust
Fatemeh Khodadust
EPEva Marie Louise Philippon
Eva Marie Louise Philippon
MSMaarten Michiel Steinz
Maarten Michiel Steinz
JHJan Piet van Hamburg
Jan Piet van Hamburg
JMJohan van Meerloo
Johan van Meerloo
CLConny van der Laken
Conny van der Laken
Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by inflammation leading to joint damage and systemic complications. Angiogenesis promotes inflammation and contributes to RA progression. This study evaluated potential anti-angiogenic effects of several compounds including small-molecule kinase inhibitors, such as sunitinib (pan-kinase inhibitor), tofacitinib (JAK-inhibitor), NIKi (NF-κB-inducing kinase inhibitor), and the integrin-targeting peptide fluciclatide, using a scratch assay and 3D spheroid-based models of angiogenesis. For all drugs tested in the low micromolar range (1–25 μM), sunitinib (as positive anti-angiogenetic control) showed marked inhibition of endothelial cell (EC) migration and sprouting, effectively reducing both scratch closure and sprout formation. Tofacitinib exhibited marginal effectiveness in the scratch assay, but performed better in the 3D models (55% inhibition), whereas NIKi showed around 50% anti-angiogenic effects in both models. Fluciclatide changed EC morphology rather than migration, and only when stimulated with synovial fluid in spheroid model did it show inhibitory effects (at ≥2.5 µM), with none below this dosage. These results highlight the potential of NIKi and tofacitinib for angiogenesis inhibition and of fluciclatide for safe diagnostic targeting of microdose in RA, as well as the need for advanced screening models that mimic RA’s complex inflammatory pro-angiogenic environment.